慢性阻塞性肺疾病和肺内受体相关药理学意义  

Chronic obstructive pulmonary disease and pharmacology in receptors of lungs

作　　者：朱卫京[1] 贺蓓[1] 

机构地区：[1]北京大学第三医院呼吸科,100083

出　　处：《国际呼吸杂志》2008年第19期1192-1196,共5页International Journal of Respiration

摘　　要：当前治疗慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）的绝大多数药物作用于气道内细胞所表达的受体。因为吸入治疗可以传送药物到关键靶位细胞，并且全身副作用较小，所以吸入治疗成为当前治疗COPD最有前途的治疗方式。β2肾上腺素受体激动剂和抗胆碱能药都靶向到大小气道平滑肌上自主神经受体，发挥支气管扩张作用，同时β2肾上腺素受体激动剂还可作用到炎症细胞等其他靶位细胞上的受体而发挥抗炎作用。糖皮质激素受体分布广泛，吸入治疗使用普遍。肺部还有许多其他受体靶位，包括趋化因子受体和孤儿受体等，相应药物正在临床开发。Most of the drugs that are currently used to treat chronic obstructive pulmonary disease （COPD） interact with receptors expressed by cells in the airways. This makes inhaled delivery efficient because it reaches the key target cells and has a low risk of systemic side effects. Both β2-agonists and anticholinergics target autonomic receptors on airway smooth muscle of large and small airways, to develop the effect on bronchodilation. They also interact with receptors expressed on other important target cells,to show anti-inflammatory effect. Glucocorticoid receptors （GR） are widely distributed so that they are best given by inhalation to interact with intracellular GR in the respiratory tract and to avoid side effects from activation of GR in extrapulmonary tissues. There are many other receptor targets that have now been identified as these may be future targets for developing novel therapies for COPD.

关 键 词：慢性阻塞性肺疾病 Β2肾上腺素受体 毒蕈碱受体 糖皮质激素受体 

分 类 号：R563.9[医药卫生—呼吸系统]